Market Overview

UPDATE: Wedbush Initiates Coverage on Curis on Potential of New Oral Therapies

Related CRIS
Curis Collaborator Aurigene Presents Preclinical Data From Oral Small Molecule PD-L1/VISTA and IRAK4 Programs at AACR-NCI-EORTC Conference
Curis Announces Oral Presentation of Phase 1 Data for CUDC-907 at 2015 ASH Annual Meeting

In a report published Friday, Wedbush analyst Christopher N. Marai initiated coverage on Curis (NASDAQ: CRIS) with an Outperform rating and $6.00 price target.

In the report, Wedbush noted, “Curis is a drug company developing oral therapies for oncology based on knowledge of cell signaling pathways. CRIS is developing CUDC-427, an antagonist of inhibitor of apoptosis proteins, key regulators of cancer cell death that may overcome chemotherapy resistance. It is also developing CUDC-907, a dual HDAC/PI3K inhibitor with differentiated PK/PD properties for DLBCL and MM. CRIS receives royalties from its partner Roche on sales of Erivedge, an approved hedgehog pathway inhibitor for advanced basal cell carcinoma.”

Curis closed on Thursday at $3.38.

Latest Ratings for CRIS

Aug 2015FBR CapitalInitiates Coverage onOutperform
Jun 2015BairdMaintainsOutperform
May 2014OppenheimerMaintainsOutperform

View More Analyst Ratings for CRIS
View the Latest Analyst Ratings

Posted-In: Christopher N. Marai WedbushAnalyst Color Initiation Analyst Ratings


Related Articles (CRIS)

View Comments and Join the Discussion!

Get Benzinga's Newsletters